Compare iShares MSCI ACWI ETF (ACWI) vs DexCom, Inc. (DXCM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
iShares MSCI ACWI ETF vs DexCom, Inc. — how do they compare? iShares MSCI ACWI ETF trades at $155.86, while DexCom, Inc. trades at $74.21 (market cap $28.39B). The key difference: iShares MSCI ACWI ETF is trading nearer its 52-week high, DexCom, Inc. nearer its low. Which is the better fit depends on your goals.
| ACWI | DXCM | |
|---|---|---|
52-Week High | $159.97 | $89.53 |
52-Week Low | $128.32 | $54.84 |
Market Cap | — | $28.39B |
Sector | — | Health |
Enterprise Value | — | $27.36B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACWI trades at $157.97, up 1.17% with a bullish technical signal from moving averages. The ETF shows strong institutional interest and positive news flow, with a dividend scheduled for June 2026. Key support lies at $156, while resistance is at $159.
Outlook remains positive due to robust EPS growth and investor inflows into global equity ETFs. Risks include overbought technical conditions and market volatility. The stock's valuation and momentum support a constructive view for long-term investors.
DXCM trades at $73.57, up 3.26% with a bullish technical outlook and strong fundamental performance. Recent earnings beats and FDA clearances for pediatric use of Stelo CGM support growth. Revenue reached $4.66B in 2025 with net income of $836.30M, reflecting a 19.31% margin. Analyst consensus is strongly bullish with an $83.78 price target.
The outlook remains positive driven by CGM market expansion and international growth, though risks include GLP-1 drug competition and execution in non-insulin markets. Valuation at 31.06 P/E is reasonable for its growth profile, with institutional sentiment favoring further upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares MSCI ACWI ETF
The fund generally will invest at least 80% of its assets in the component securities of its underlying index and in investments that have economic characteristics that are substantially identical to the component securities of its underlying index. The index is a free float-adjusted market capitalization index designed to measure the combined equity market performance of developed and emerging markets countries.
Read more on ACWI →About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →
